1. Alm A, Widengard I, Kjellgren D, et al. Latanoprost administered once daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol.Br J Ophthalmol 1995;79:12-16.
2. Alm A, Stjernschantz J, the Scandin-avian Latanoprost Study Group. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Ophthalmology 1995;102: 1743-1752.
3. Camras CB, the United States Latano-prost Study Group. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma. A six-month, masked, multicenter trial in the United States. Ophthalmology 1996; 103:138-147.
4. Watson P, Stjernschantz J, the Latano-prost Study Group. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. Ophthalmology 1996; 103:126-137.
5. Mishima HK, Masuda K, Kitazawa Y, et al. A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension. A 12-week study. Arch Ophthalmol 1996;114:929-932.
|
6. Camras CB, Alm A, Watson P,Stjernschantz J, the Latanoprost Study Groups. Latanoprost, a prostaglandin analog, for glaucoma therapy. Efficacy and safety after 1 year of treatment in 198 patients. Ophthalmology 1996;103: 1916-1924.
7. Watson PG, the Latanoprost Study Group. Latanoprost two years' experi-ence of its use in the United Kingdom. Ophthalmology 1998;105:82-87.
8. Toris CB, Camras CB, Yablonski ME. Effects of PhXA41, a new prostaglandin
F2 analog, on aqueous humor dynamics in human eyes. Ophthalmology 1993; 100:1297-1304.
9. Ziai N, Dolan JW, Kacere RD, Brubaker RF. The effects on aqueous dynamics of PhXA41, a new prostaglandin F2 analogue, after topical application in normal and ocular hypertensive human eyes. Arch Ophthalmol 1993;111:1351-1358.
10. Stjernschantz J, Selen G, Sjoquist B, Resul B. Preclinical pharmacology of latanoprost, a phenyl-substituted PGF2 analogue. Adv Prostaglandin Thrombo-xane Leukot Res 1995;23:513-518.
|
11. Hotehama Y, Mishima HK. Clinical efficacy of PhXA34 and PhXA41, two novel prostaglandin F2-isopropyl ester analogues for glaucoma treatment. Jpn J Ophthalmol 1993;37:259-269.
12. Linden C, Nuija E, Alm A. Effects on IOP restoration and blood-aqueous barrier after long term treatment with latano-prost in open angle glaucoma and ocular hypertension. Br J Ophthalmol 1997;81:370-372.
13. Widengard I, Maepea O, Alm A. Effects of latanoprost and dipivefrin, alone or combined, on intraocular pressure and on blood-aqueous barrier permeability. Br J Ophthalmol 1998;82:404-406.
14. Diestelhorst M, Roters S, Krieglstein GK. The effect of latanoprost 0.005% once daily versus 0.015% twice daily on intraocular pressure and aqueous humour protein concentration in glau-coma patients. A randomized, double-masked comparison with timolol 0.5%. Graefes Arch Clin Exp Ophthalmol 1997;235:20-26.
15. Wistrand PJ, Stjernschantz J, Olsson K. The incidence and time-course of latanoprost-induced iridial pigmentation as a function of eye color. Surv Ophthalmol 1997;41 (Suppl 2):S129-S138.
|
